Disclaimer:
This blog is for informational purposes only and should not be taken as medical advice. Content is sourced from third parties, and we do not guarantee accuracy or accept any liability for its use. Always consult a qualified healthcare professional for medical guidance.
Ocular melanoma is a rare eye cancer arising from melanocytes in the uveal tract (iris, ciliary body, choroid; 85%), conjunctiva (5%), or orbit. Choroidal is most common. In 2025, ~3,140 US cases, median age 55, slightly more in men/light-eyed individuals.
Symptoms include blurred vision, floaters, visual field loss, dark iris spot, pupil shape change, or bulging eye. Many are asymptomatic, found during eye exams. Advanced causes pain, glaucoma, or detachment. In 2025, symptoms prompt urgent ophthalmology referral.
Causes include UV exposure (conjunctival), genetic mutations (GNAQ/GNA11 in uveal), fair skin/eyes, dysplastic nevus syndrome. BAP1 mutations increase metastasis risk. No strong lifestyle links. In 2025, genomics show immune evasion in metastasis.
Diagnosis uses slit-lamp exam, ophthalmoscopy, ultrasound for thickness, fluorescein angiography, and biopsy (fine-needle). CT/MRI/PET for staging. Molecular testing for GNAQ/BAP1. In 2025, AI imaging improves detection.
Small melanomas use observation or laser (photodynamic). Medium/large use plaque brachytherapy, proton beam radiation, or enucleation. Metastatic uses immunotherapy (tebentafusp for HLA-A*02:01+). In 2025, targeted therapies improve responses.
In 2025, 5-year survival is 80-85% for localised, 15% for metastatic (liver common). Tebentafusp extends survival to 21 months. By 2030, vaccines and ADCs could raise metastatic survival to 30%.
The information for ocular melanoma is sourced from Mayo Clinic’s “Eye melanoma – Symptoms and causes” for symptoms; NORD’s “Ocular Melanoma – Symptoms, Causes, Treatment” for causes; OncoDaily’s “Ocular Melanoma: Symptoms, Causes, Stages, Diagnosis and Treatment” for stages; Mayo Clinic’s “Eye melanoma – Diagnosis and treatment” for treatment; Macmillan’s “Eye cancer (ocular melanoma) – symptoms, staging, treatment” for overview; Cleveland Clinic’s “Eye Cancer: Symptoms, Types & Treatment” for types; NCBI’s “Ocular Melanoma” for prognosis; NCI’s “Intraocular (Uveal) Melanoma Treatment” for treatment; Cancer Council’s “Eye cancer (ocular melanoma)” for information.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
1. Scan at your preferred center.
2. Written report from a specialist radiologist sent via email.
3. Access and download your scan images digitally.
4. Upon request, we can send the report and images to your doctor or hospital.
5. For self-referred patients, there is an additional charge of £30, which includes scan referral and a discussion with a private GP before and after the scan